EntryPoint Capital’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
N
EntryPoint Capital's REGN Position: Q4 2025 in Review
EntryPoint Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 683 shares — an estimated $384K sold.
EntryPoint Capital first reported a position in REGN in Q4 2023 and held it in 5 quarters. The position peaked at $414K in Q1 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.
- EntryPoint Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- EntryPoint Capital sold 683 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $384K.
- EntryPoint Capital first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 5 quarters.
- EntryPoint Capital's Regeneron Pharmaceuticals position peaked at $414K in Q1 2025.
- 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.
Based on EntryPoint Capital's 13F filing for Q4 2025, filed 12 Feb 2026.